ENTERA BIO LTD. Cash And Cash Equivalents
ENTERA BIO LTD. (ENTX) had Cash And Cash Equivalents of $26.93 million as of 2021-06-30, per its 6-K filed 2021-08-16.
Discontinued › Balance Sheet › Assets
ifrs-full:CashAndCashEquivalents · last filed 2021-08-16
- 2021-06-30: Cash And Cash Equivalents $26.93M.
- 2020-12-31: Cash And Cash Equivalents $8.59M.
- 2020-06-30: Cash And Cash Equivalents $9.77M.
- 2019-12-31: Cash And Cash Equivalents $15.19M.
| Period end | Cash And Cash Equivalents |
|---|---|
| 2021-06-30 | $26.93M 6-K · filed 2021-08-16 |
| 2020-12-31 | $8.59M 6-K · filed 2021-08-16 |
| 2020-06-30 | $9.77M 6-K · filed 2021-08-16 |
| 2019-12-31 | $15.19M 6-K · filed 2021-08-16 |
| 2019-06-30 | $7.39M 6-K · filed 2020-08-20 |
| 2018-12-31 | $7.51M 20-F · filed 2021-03-18 |
| 2017-12-31 | $11.75M 20-F · filed 2021-03-18 |
| 2016-12-31 | $4.16M 20-F · filed 2020-03-26 |
| 2015-12-31 | $1.21M 20-F · filed 2019-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |